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Abstract 
The expression of subunits of mitochondrial respiratory complexes and components of 
the protein synthesis machinery from the nucleolus to the ribosome was analyzed in 
the mediodorsal thalamus in seven cases of Fatal Familial Insomnia (FFI) compared 
with age-matched controls. NDUFB8 (complex I subunit), SDHB (complex II subunit), 
UQCRC2 (complex III subunit), COX2 (complex IV subunit) and ATP50 (complex V 
subunit) expression levels, as revealed by western blotting, were reduced in FFI. 
Voltage-dependent anion channel (VDAC) and ATP5H were also reduced due to the 
marked depopulation of neurons. In contrast, a marked increase in superoxide 
dismutase 2 (SOD2) was found in reactive astrocytes thus suggesting that astrocytes 
are key factors in oxidative stress responses. The histone-binding chaperones 
nucleolin and nucleoplasmin 3, and histone H3 di-methylated K9 were markedly 
reduced together with a decrease in the expression of protein transcription elongation 
factor eEF1A. These findings show severe impairment in the expression of crucial 
components of mitochondrial function and protein synthesis in parallel with neuron loss 
in mediodorsal thalamus at terminal stages of FFI. Therapeutic measures must be 
taken long before the appearance of clinical symptoms to prevent the devastating 
effects of FFI.  
 
 
Key words: Fatal familial insomnia, mitochondria, protein synthesis, mitochondrial 
respiratory chain, nucleolus, ribosome  
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Introduction  
 
Prion protein is encoded by PRNP located on the short arm of chromosome 20 in 
humans. The second exon of PRNP encodes a protein of 253 amino acids that is 
truncated post-translationally to remove twenty-two amino acids at the amino-terminal 
and twenty-three amino acids at the carboxyl-terminal, being replaced at this site by the 
addition of a glycosylphosphatidylinositol (GPI) anchor. Additional putative 
glycosylation in two asparagine sites gives rise to three isoforms, fully di-glycosylated, 
mono-glycosylate and non-glycosylated prion protein (3). Mutations in PRNP are 
causative of genetic prion diseases, some of which are manifested as familial 
Creutzfeldt-Jakob disease (CJD), the phenotype of which depends on the site of PRNP 
mutation and also on the polymorphism of codon 129 in PRNP (3).  
Fatal familial insomnia (FFI) is an autosomal dominant prion disease caused by a 
D178N mutation in PRNP in combination with methionine (Met) at codon 129 in the 
mutated allele of the same gene (D178N-129M haplotype) (15, 23, 24, 26, 27, 31). 
Homozygosity, either methionine-methionine or valine-valine, at codon 129 in the 
normal allele of PRNP results in acceleration of clinical symptoms and shorter duration 
of the disease (5, 13, 29). 
Clinically, FFI is principally manifested as sleep disturbances with insomnia, sleep 
fragmentation, and altered arousal and dreaming, accompanied by autonomic 
disturbances including increased salivation and sweating, tachycardia, hypertension 
and impotence, as well as spontaneous and evoked myoclonus, among other 
neurological symptoms (5, 12, 14, 17, 20, 21, 29, 38).  
Clinical symptoms reflect major atrophy of the anterior ventral and mediodorsal limbic 
nuclei of the thalamus that extends to the pulvinar, ventral anterior and ventral medial 
thalamic nuclei with disease progression. The inferior olives are the other major targets 
in FFI. Severe neuron loss and astrogliosis without spongiform change in these 
regions, in the context of familial disease, are the neuropathological characteristics of 
FFI. Moderate astrogliosis without neuron loss is common in the periaqueductal gray 
matter and hypothalamus. Involvement of the inner temporal cortex, including CA1 
region of the hippocampus, cingular cortex and other areas of the neocortex, is variable 
and depends on the duration of the disease, which in turn largely depends on the 
codon 129 polymorphism (14, 21, 25, 27, 29).  
The deposition of abnormal prion protein (PrPSc) varies from one region to another in 
FFI. Immunohistochemistry usually shows small granular deposits in the temporal 
neocortex in cases with relatively long duration, whereas PrPSc deposition in thalamus 
is very scanty, if present. However, western blotting identifies a particular pattern 
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characterized by a weak band of proteinase-resistant non-glycosylated PrPSc at 19 kDa 
(type 2 PrP) and relatively strong bands of mono-glycosylated and di-glycosylated 
PrPSc which disappear following PNGase digestion, giving rise to a robust non-
glycosylated band (14, 29, 30, 31).  
Recent studies of gene expression profiling have shown altered gene expression in the 
thalamus in FFI cases when compared with controls. The main changes correspond to 
the following biological processes: transcription, regulation of transcription, protein 
biosynthesis, protein folding, protein transport, RNA splicing, electron transport chain, 
oxidative phosphorylation, energy metabolism, transport, and oxidation reduction (37). 
Proteomics methods have also been employed to assess altered protein profiles in FFI. 
Proteins involved in protein export and oxidative phosphorylation, as well as proteins 
involved in other neurodegenerative diseases as Alzheimer’s disease and Parkinson’s 
disease have been identified in the cortex and cerebellum (35). Unfortunately, the 
thalamus was not examined.     
Because of the limited knowledge about altered metabolic pathways in FFI, the present 
study was designed to learn about alterations of two major complex pathways, one 
regulating energy metabolism, and particularly mitochondrial function, and the other 
protein synthesis. The study was performed on post-mortem samples of the thalamus 
of seven well-characterized cases of FFI which were analysed using combined qRT-
PCR, western blotting and immunohistochemistry.  
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Material and methods 
 
Human samples 
All the cases were from the Basque Country in the north of Spain where FFI has a 
relative high incidence due to a founder effect in a historically small rural community 
with not uncommon endogamy (32). This study was focused on the mediodorsal 
thalamus from seven FFI cases and seven controls (Table I).  
All FFI cases were males, had the mutation D178N and were Met/Met homozygous at 
the codon 129 of PRNP. The most common age at onset was between 47 and 57 
years (five cases) with the exception of one young person aged 36 and one old 
individual aged 70. The duration of the disease was between 6 and 16 months 
independently of the age at onset.     
Brain tissue was obtained from the Brain Bank of the Araba University Hospital and 
Basque Biobank for Research (O+eHun) and the Institute of Neuropathology Biobank 
following the guidelines of the Spanish legislation on this matter and the approval of the 
local ethics committees. The post-mortem interval between death and tissue 
processing was between 4h 15min and 22h 50min. One hemisphere was immediately 
cut in coronal sections, 1cm thick, and selected areas of the encephalon were rapidly 
dissected, frozen on metal plates over dry ice, placed in individual air-tight plastic bags, 
numbered with water-resistant ink and stored at -80ºC until use. The other hemisphere 
was fixed by immersion in 4% buffered formalin for 3 weeks. Neuropathological 
examination in all cases was routinely performed on twenty selected de-waxed paraffin 
sections comprising different regions of the cerebral cortex, diencephalon, thalamus, 
brain stem and cerebellum which were stained with haematoxylin and eosin, Nissl 
staining, and for immunohistochemistry to microglia using antibodies Iba1 and CD68, 
glial fibrillary acidic protein (GFAP), β-amyloid, phosphorylated tau (clone AT8), PrP 
(using the 3F4 antibody without and with pre-treatment with proteinase K), α-synuclein, 
TDP-43, ubiquitin and p62. FFI cases were pre-treated with formic acid. Age-matched 
control cases had not suffered from neurologic, psychiatric, or metabolic diseases 
(including metabolic syndrome), and did not have abnormalities in the 
neuropathological examination excepting sporadic Alzheimer’s disease-related 
pathology stages I-II/0 of Braak and Braak.  
RNA extraction  
RNA was obtained from about 100mg of the dorsomedial thalamus of FFI cases and 
controls using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, GE) following the protocol 
provided by the supplier. All samples were treated with RNase-free DNase Set 
(Qiagen) for 15min to eliminate genomic DNA contamination. The concentration of 
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each sample was measured using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA) at 340 nm. RNA integrity was assessed with the RNA 
Integrity Number (RIN value) determined with the Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, CA, USA) (34). RIN values were similar in control and FFI cases (Table I). 
Retro-transcription reaction 
Retro-transcription reaction of RNA samples was carried out with the High-Capacity 
cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) using 1,000ng of RNA for 
each sample following the protocol provided by the supplier using a Gene Amp 9700 
PCR System thermos-cycler (Applied Biosystems). RNA samples without reverse 
transcriptase were processed in parallel as controls of the reaction. No amplifications 
were obtained in any cases.  
Real-time polymerase chain reaction (qRT-PCR) 
Quantitative RT-PCR assays were performed in duplicate on cDNA samples obtained 
from the retro-transcription reaction diluted 1:20 in 384-well optical plates (Kisker 
Biotech, Steinfurt, GE) using the ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems). The reactions were carried out using 20xTaqMan Gene 
Expression Assays for genes involved in protein synthesis, energetic metabolism and 
purine metabolism, and 2xTaqMan Universal PCR Master Mix (Applied Biosystems). 
TaqMan probes used in the study are shown Table II. The reactions were conducted 
with the following parameters: 50ºC for 2 min, 95ºC for 10 min, 40 cycles at 95ºC for 15 
sec and 60ºC for 1 min. The data were captured using the Sequence Detection 
Software (SDS version 2.2, Applied Biosystems). Threshold cycle (CT) data for each 
sample were analysed with the Livak Method or double delta CT (∆∆CT) method (19). 
First, delta CT (∆CT) values were calculated as the normalized CT values for each 
target gene in relation to the endogenous control X-prolyl aminopeptidase P1 
(XPNPEP1) used as house-keeping gene (9). Second, ∆∆CT values were obtained 
from the ∆CT of each sample minus the mean ∆CT of control samples. The fold 
change was determined using the equation 2-∆∆CT. Mean fold-change values for every 
region between FFI cases and controls were analysed with the Student’s t test using 
GraphPad Prism 6 when the distribution was normal as revealed by the Kolmogorov-
Smirnov test. If the distribution was not normal, mean fold-changes were analysed with 
the Mann-Whitney Test. Differences between groups were considered statistically 
significant at * p < 0.05, ** p < 0.01, and *** p < 0.001. 
Protein extraction and western-blotting  
Thalamus samples (0.1g) were homogenized using lysis buffer composed of 100mM 
Tris pH 7, 100mM NaCl, 10mM EDTA, 0.5% NP-40 and 0.5% sodium deoxycolate plus 
protease and phosphatase inhibitors (Roche Molecular Systems, Pleasanton, CA, 
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USA). Samples were centrifuged at 4°C for 5 min at 10,000g USING Eppendorf 
centrifuge 5417R (Eppendorf®, Hamburg, GE) and the supernatants obtained were 
stored at -80ºC. Proteins were separated in sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Control of protein loading was carried out with 
Coomassie blue staining. Proteins were then electrophoretically transferred to 
nitrocellulose membranes using the Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) 
at 60mA/membrane for 90 min). Non-specific bindings were blocked by incubation in 
5% milk in Tris-buffered saline (TBS) containing 0.2% Tween for 1 h at room 
temperature. After washing, the membranes were incubated at 4°C overnight with one 
of the primary antibodies listed in Table III in TBS containing 5% albumin and 0.2% 
Tween. Afterwards, the membranes were incubated for 1 h with the appropriate HRP-
conjugated secondary antibody (1:1,000, Dako, Glostrup, Denmark), and the immune 
complexes were visualized with a chemiluminescence reagent (ECL, Amersham, GE 
Healthcare, Buckinghamshire, UK). Densitometry of western blot bands was assessed 
with the TotalLab program (TotalLab Quant, Newcastle, UK) and analysed with 
Graphpad Prism using Student’s t test when the distribution was normal and Mann-
Whitney test when the distribution was not normal, as assessed with the Kolmogorov-
Smirnov normality test. Differences were considered statistically significant at * p<0.05; 
** p<0.01; *** p<0.001. 
Immunohistochemistry  
Immunohistochemical study was performed in 4 µm-thick dewaxed paraffin sections of 
the thalamus. Endogenous peroxidases were blocked with peroxidase (Dako, Glostrup, 
Denmark) followed by 10% normal goat serum. The primary antibodies are shown in 
Table III. Following incubation with the primary antibody at room temperature overnight, 
the sections were incubated with EnVision+ system peroxidase (Dako) at room 
temperature for 15min. The peroxidise reaction was visualized with diaminobenzidine 
(DAB) and H2O2. No antigenic peptides were available to carry out pre-adsorption 
studies of primary antibodies. However, the omission of the primary antibody in some 
sections was used as a control of the immunostaining; no signal was obtained after 
incubation with only the secondary antibody.  Sections were slightly counterstained 
with haematoxylin. Quantification of Nissl-stained and immunoreative cells identified 
with antibodies against glial fibrillary acidic protein (GFAP), CD68, voltage dependent 
anion channel (VDAC), nucleolin (NCL), nucleplasmin 3 (NPM3), histone H3K9me2, 
ATP5H protein and superoxide dismutase 2 (SOD2) was carried out in the mediodorsal 
thalamus in five controls and five FFI cases (two fields per case) at a magnification of 
x200 which corresponds to an area of 450x280 µm2. Results were expressed as mean 
values ± standard deviation (SD).   
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Results 
 
1. General neuropathological findings 
Severe neuronal loss and marked astrocytic gliosis was observed in every case in the 
mediodorsal and anterior nuclei of the thalamus, and inferior olives; the ventral nuclei 
of the thalamus and the entorhinal cortex were variably affected (five and six of seven 
cases, respectively). Spongiform change was not seen in the mediodorsal thalamus 
and only in the entorhinal cortex when affected. PrP. Discrete astrogliosis was also 
found in the periaqueductal grey matter. Representative changes in the mediodorsal 
thalamus and entorhinal cortex compared with corresponding regions in age-matched 
controls are shown in Figure 1. Neuron loss in the mediodorsal thalamus was severe 
accounting for about 80-90%; only isolated small neurons can be seen in some cases.  
Microglial response was analyzed using the antibodies Iba1 which identifies microglia 
and CD68 which recognizes active microglia. Increased numbers of Iba1- and CD68-
immunoreactive cells was found in the mediodorsal thalamus, particularly in two of 
seven cases, and entorhinal cortex in the six cases in which this region was affected. 
Details of cell types are recognized at higher magnification (Fig. 1 inserts)  
Immunohistochemistry using the 3F4 antibody disclosed synaptic and fine granular 
proteinase-resistant PrP immunoreactivity in the entorhinal cortex, whereas PrP 
immunoreactivity was absent in the mediodorsal thalamus in FFI cases (Fig. 2). As 
expected no proteinase-resistant PrP was present in control cases (data not shown).    
 
2. Mitochondria and respiratory chain 
2a. mRNA expression  
Eleven genes which codify for proteins that are part of electron transport chain 
complexes, one gene that encodes a translocase of the mitochondrial outer membrane 
(TOMM40) and two genes that codify for lysosomal ATPase (ATP6V0B and 
ATP6V1H1) were analysed in the thalamus of FFI samples. Complex I was 
represented by NDUFA2, NDUFA7, NDUFA10, NDUFB3, NDUFB7, NDUFB10, 
NDUFS7 and NDUFS8; complex II by SDHB; complex III by UQCR11 and UQCRB; 
complex IV by COX7A2L and COX7C; and complex V by ATP5D, ATP5G2, ATP5H, 
ATP5L and ATP5O. Only ATP5D was down-regulated (Student’s t test p < 0.01).  
Detailed data are shown in Supplementary Table I.  
 
2b. Protein expression of selected mitochondrial proteins  
2b1: Expression levels of mitochondrial proteins in mediodorsal thalamus. 
NDUFB8 (complex I subunit), SDHB (complex II subunit), UQCRC2 (complex III 
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subunit), COX2 (complex IV subunit) and ATP50 (complex V) expression levels, as 
revealed by western blotting, were reduced in mediodorsal thalamus in FFI, whereas 
UQCRB (complex III) and ATP5A (complex V subunit) expression was similar in FFI 
and controls. Densitometric analysis using β-actin and VDAC for normalisation showed 
similar results, The only exception between β-actin and VDAC normalisation was 
ATP5O which presented significant differences when using β-actin between control 
group and FFI group but ony a tendency with a p-value 0.09 when using VDAC for 
normalisation. Together, these results indicated that reduced protein expression of 
proteins of the respiratory chain was not merely the consequence of a reduced number 
of mitochondria, but was also related to the selective loss of certain vulnerable subunits 
(Figure 3). Detailed data are shown in Supplementary Table II.  
 
 
2b2 Voltage-dependent anion channel (VDAC), ATP5H and superoxide dismutase 
2 (SOD2) in mediodorsal thalamus in FFI 
Consecutive sections were stained with Nissl staining and processed for 
immunohistochemistry to VDAC, ATP5H and SOD2. Nissl staining served to illustrate 
the severe loss of neurons in the mediodorsal thalamus in FFI when compared with 
controls, together with the increase in the number of small nuclei corresponding, in part 
to astrocytes (Fig. 4 A, B).    
In control brains, neurons presented strong VDAC immunoractivity, punctuate ATP5H 
immunoreactivy and weak SOD2 immunoreactivity in the cytoplasm. Marked decrease 
in VDAC immunoreactivity related to the loss of neurons was observed in the 
mediodorsal thalamus in FFI when compared with controls (Figure 4 C, D). This was 
accompanied by general decrease of ATP5H immunoreactivity due to neuron loss 
together with enhanced visualization of ATP5H immunostaining in reactive astrocytes 
(Figure 4 E, F). Marked SOD2 immunoreactivity was found in reactive astrocytes 
(Figure 4 G, H). Details of cell types are recognized at higher magnification (Fig. 4 
inserts). Quantitative data are shown in Table IV.  
 
3. Molecular pathways involved in protein synthesis 
3a. mRNA expression of ribosomal proteins RPL and RPS, nucleolar proteins, 
and 18S rRNA and 28S rRNA  
Nucleolin (NCL), nucleophosmin (NPM1) and eukaryotic upstream binding factor 
(UBTF) gene expression levels were analysed in FFI cases and controls. NPM1 was 
up-regulated in the thalamus in FFI (Figure 5).  
28S rRNA was also up-regulated in FFI cases (Figure 5).  
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The expression of nine RPL (RPL5, RPL7, RPL21, RPL22, RPL23A, RPL26, RPL27, 
RPL30 and RPL31) and seven RPS (RPS3A, RPS5, RPS6, RPS10, RPS13, RPS17 
and RPS20) genes was assessed in the mediodorsal thalamus in FFI cases and 
controls. RPS17 and RPS20 were up-regulated (Figure 5). Detailed data are shown in 
Supplementary Table III.  
3b. Immunohistochemistry of selected molecules involved in protein synthesis 
In control mediodorsal thalamus, anti-NCL antibodies weakly decorated the nucleolus 
and heavily the cytoplasm of neurons. NCL immunoreactivity was weak if present in 
glial cells under the same staining conditions. Anti-nucleoplasmin 3 (NPM3) antibodies 
decorated the nucleolus of neurons. Histone H3 di-methylated K9 (H3K9me2), which 
modulates NCL and NPMs function in rRNA transcription (Tamada et al., 2006; Cong 
et al., 2012), was strongly expressed in the nucleus of neurons (Figure 6 A, C, E).   
Immunoreactivity of NCL and (NPM3) was reduced in the mediodorsal thalamus in FFI 
cases when compared with controls (Figure 6 B, D). H3K9me2 expression was also 
decreased in the thalamus in FFI (Figure 6 F). NCL, NPM3 and H3K9me2 reduction in 
the mediodorsal thalamus was clearly due to the loss of neurons; reactive glial cells 
(already represented in previous figures) did not show increased immunoreactivity. 
Quantitative data are shown in Table IV. 
3c. Expression of nucleolin, and initiation and elongation factors, in mediodorsal 
thalamus 
Expression levels of nucleolin were markedly decreased in the mediodorsal thalamus 
in FFI (Figure 7) as expected from the immunohistochemical studies. Regarding 
initiation and elongation factors, only eEF1A was significantly decreased in the 
mediodorsal thalamus of FFI cases (Figure 7). Detailed data are shown in 
Supplementary Table IV.  
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Discussion  
 
All the cases examined in the present series are males, have the D178N mutation and 
are Met/Met homozygous at the codon 129 of PRNP. In spite of the variable age at 
onset, disease duration was between 6 and 9 months; the neuropathological findings 
were similar from one case to another; therefore, this series conforms a relative 
homogeneous population. General neuropathological findings in these series are 
similar to those already described in FFI (14, 21, 25, 27, 29). Based on these features 
and on the small number of cases, no attempt was made to divide the sample into 
subgroups. 
The post-mortem delay between death and processing was longer in the FFI group 
when compared with the controls. However, the RIN values were similar in both groups 
and protein preservation as revealed by western blotting and immunohistochemistry 
was similar in controls and diseased brains.           
Brain hypo-metabolism, as revealed by [18F]-2-fluoro-2-deoxy-D-glucose and positron 
emission tomography PET to study regional cerebral glucose utilization, predominates 
in the thalamus and cingular cortex, but the basal and lateral frontal cortex, the caudate 
nucleus, and the middle and inferior temporal cortex are also moderately affected (7). 
The neurodegenerative process starts between 13 and 21 months before the clinical 
symptoms and it is manifested by hypo-metabolism in the thalamus and impaired 
thalamic sleep spindle formation in pre-clinically affected family members (6). The 
present findings are in line with functional studies showing down-regulation of ATP5D 
mRNA expression as revealed by qRT-PCR, and significant reduction in the expression 
of NDUFB8 (complex I subunit), SDHB (complex II subunit), UQCRC2 (complex III 
subunit), COX2 (complex IV subunit) and ATP5O (complex V subunit) protein levels, as 
assessed with western blotting of total homogenates of the mediodorsal thalamus. 
Immunohistochemistry discloses the origin of reduced mitochondrial expression as 
being linked to severe neuron loss, as practically no neurons were stained with 
antibodies against VDAC and ATP5H. These changes are accompanied by increased 
oxidative stress responses manifested by increased SOD2 immunostaining in reactive 
astrocytes.  
The expression of molecules involved in the machinery of protein synthesis was also 
altered in the mediodorsal thalamus in FFI when compared with controls. Curiously, 
increased mRNA expression of NPM1, 28S rRNA, RPS17 and RPS20 is in contrast to 
the decreased protein expression levels of the histone-binding chaperones nucleolin 
(NCL) and nucleoplasmin 3 (NPM3), which regulate rRNA transcription (2, 4, 10, 11, 
16, 18, 28), and of histone H3 di-methylated K9 (H3K9me2), which modulates NCL and 
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NPMs function in rRNA transcription (4, 36). Changes in protein expression are clearly 
related to the dramatic reduction of neurons as disclosed by immunohistochemistry.  
Regarding the protein expression of initiation and elongation factors of protein 
transcription, only eEF1A is down-regulated. However, the role of this factor is crucial, 
as elongation occurs when eEF1A is activated following GTP binding and forms a 
complex with aminoacyl-tRNA, which recognizes the speciﬁc sequence in mRNA at the 
ribosome. Once the interaction of the codon in mRNA with the anti-codon in tRNA is 
decoded, eEF1A-GDP is hydrolyzed, released from the ribosome, and recycled into its 
active form by eEF1B. eEF2 assists in the precise codon location at the ribosome (1, 8, 
33, 39).  
Present molecular studies show reduced expression of proteins linked to the 
mitochondrial respiratory chain involving subunits encoded by genomic DNA of the five 
mitochondrial complexes in line with a marked reduction in the number of neurons as 
revealed by morphological and immunohistochemical studies, as well as decreased 
metabolism as shown by PET studies in vivo in the mediodorsal nucleus of the 
thalamus in FFI. Altered machinery of protein synthesis is also manifested by 
decreased expression of nucleolar chaperones, histone modifications and decreased 
methylation of DNA in the mediodorsal thalamus in FFI. Alterations in the levels of 
proteins do not correlate with modifications in the expression of corresponding mRNA 
levels, which are often maintained or even up-regulated. This may be explained by 
failed compensatory mechanisms in the remaining neurons or by increased RNA 
expression in reactive astrocytes. In favor of the latter, is the dramatic increase of 
reactive astrocytes and the increased expression of superoxide dismutase 2 which tags 
reactive astrocytes as crucial components of oxidative stress responses in the 
mediodorsal thalamus in FFI.        
All these changes are observed at terminal stages of the disease, with devastating 
effects on selected brain regions. Little can be done at this stage but efforts must be 
made at preclinical stages to prevent mitochondrial and protein synthesis havoc at 
advanced stages of the disease.    
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Table I: Summary of the main clinical and pathologic features of cases used in the 
present study. PMD: post-mortem delay; C: control; FFI; fatal familial insomnia; RIN: 
RNA integrity number; Thal: mediodorsal thalamus  
 
 
 
Case Sex Age PMD Neuropathology RIN Thal 
1 M 67 14h40min C 6 
2 M 61 4h30min C 7.2 
3 M 59 4h15min C 6.6 
4 W 66 12h10min C 6.7 
5 M 76 4h15min C 6 
6 M 81 11h40min C 6 
7 M 57 5h C 6.9 
8 M 53 12h10min FFI 7.9 
9 M 56 22h50min FFI 5.3 
10 M 36 17h30min FFI 6.4 
11 M 70 15h30min FFI - 
12 M 50 12h30min FFI 6.8 
13 M 47 3h30min FFI 8.2 
14  M 54 9h50min FFI 7.5 
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Table II: Abbreviated names of genes, their full names, and TaqMan probe references 
used for the study of mRNA expression of mitochondria, protein synthesis and purine 
metabolism enzymes including GUS-β and XPNPEP1 used for normalisation. 
 
Gene Gene full name Taqman probes  
XPNPEP1 X-propylaminopeptidase 1 Hs00958026_m1 
 
Mitochondria  
 
NDUFA2 
NADH Dehydrogenase (Ubiquinone) 1 apha 
subcomplex, 2, 8kDa Hs04187282_g1 
NDUFA7 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 7, 14.5kDa Hs01561430_m1 
NDUFA10 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa Hs01071117_m1 
NDUFB3 
NADH Dehydrogenase (Ubiquinone) 1 Beta 
subcomplex, 3, 12kDa Hs00991297_g1 
NDUFB7 
NADH Dehydrogenase (Ubiquinone) 1 Beta 
subcomplex, 7, 18kDa Hs00188142_m1 
NDUFB10 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa Hs00605903_m1 
NDUFS7 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 7, 20kDa (NADH-coenzyme Q 
reductase) Hs00257018_m1 
NDUFS8 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 8, 23kDa (NADH-coenzyme Q 
reductase) Hs00159597_m1 
SDHB 
Succinate dehydrogenase complex, subunit B, 
Iron Sulfur (Ip) Hs01042482_m1 
UQCR11 
Ubiquinol-cytochrome C reductase, complex III 
subunit XI Hs00199138_m1 
UQCRB 
Ubiquinol-cytochrome C reductase binding 
protein Hs01890823_s1 
COX7A2L 
cytochrome c oxidase subunit VIIa polypeptide 2 
like Hs00190880_m1 
COX7C Cytochrome C oxidase subunit VIIc Hs01595220_g1 
ATP5D 
ATP Synthase, H+ transporting, mitochondrial 
F1 complex, Delta Subunit Hs00961521_m1 
ATP5G2 
ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit C2  Hs01086654_g1 
ATP5H 
ATP Synthase, H+ transporting, mitochondrial 
Fo complex, subunit D Hs01046892_gH 
ATP5L 
ATP Synthase, H+ transporting, mitochondrial 
Fo complex, subunit G Hs00538946_g1 
ATP5O 
ATP Synthase, H+ transporting, mitochondrial 
F1 complex, O subunit Hs00426889_m1 
ATP6V0B 
ATPase, H+ transporting, lysosomal 21kDa, V0 
subunit b Hs01072388_m1 
ATP6V1H 
ATPase, H+ transporting, lysosomal 50/57kDa, 
V1 subunit H Hs00977530_m1 
TOMM40 
Translocase of outer mitochondrial membrane 
40 Hs01587378_mH 
 
Protein synthesis  
 
NCL nucleolin Hs01066668_m1 
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NPM1 nucleophosmin /protein B23) Hs02339479_g1 
UBTF eukaryotic upstream binding factor  Hs01115792_g1 
18S rRNA  eukaryotic 18S rRNA Hs99999991_s1 
28S rRNA  RNA, 28S ribosomal  Hs03654441_s1 
RPL5 ribosomal protein L5 Hs03044958_g1 
RPL7 ribosomal protein L7 Hs02596927_g1 
RPL21 ribosomal protein L21 Hs00823333_s1 
RPL22 ribosomal protein L22 Hs01865331_s1 
RPL23A ribosomal protein L23A Hs01921329_g1 
RPL26 ribosomal protein L26 Hs00864008_m1 
RPL27 ribosomal protein L27 Hs03044961_g1 
RPL30 ribosomal protein L30 Hs00265497_m1 
RPL31 ribosomal protein L31 Hs01015497_g1 
RPS3A ribosomal protein S3A Hs00832893_sH 
RPS5 ribosomal protein S5 Hs00734849_g1 
RPS6 ribosomal protein S6 Hs04195024_g1 
RPS10 ribosomal protein S10 Hs01652370_gH 
RPS13 ribosomal protein S13 Hs01011487_g1 
RPS16 Ribosomal protein S16 Hs01598516_g1 
RPS17 ribosomal protein S17 Hs00734303_g1 
RPS20 Ribosomal protein S20 Hs00828752_gH 
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Table III: List of antibodies used for western blotting and immunohistochemistry. 
 
 
Antibody Reference Supplier Host wb 
dilution 
ihq 
dilution 
Nucleolin Ab22758 Abcam (Cambridge, UK) rb 1/100 1/1,000  
anti-eukaryotic translation initiation factor 2 
(eIF2-α) 5A5 
Thermo Scientific (Waltham, 
MA, USA) m  1/50   
anti-phospho-eIF2-alpha pSer51 (p-EIF2-α) S.674.5 Thermo Scientific (Waltham, 
MA, USA) rb 1/50   
anti-eukaryotic translation initiation factor 5 
(eIF5) sc-282 
Santa Cruz (Dallas, Texas, 
USA) rb 1/400    
anti-eukaryotic elongation factor 1A 
(eEF1A) 2551 
Cell signaling (Danvers, MA, 
USA) rb 1/100    
anti-eukaryotic elongation factor 2 (eEF2) 2332 Cell signaling (Danvers, MA, 
USA) rb 1/500    
Total OXPHOS Antibody Cocktail ab110411 Mitoscienes, Abcam 
(Cambridge, UK) m 1/1,000   
ATP5O (OSCP Antibody) 
10994-1-AP Proteintech (Chicago, USA) rb 1/1,000   
UQCRB 10756-1-AP Proteintech (Chicago, USA) rb 1/250   
VDAC1 Ab15895 Abcam (Cambridge, UK) rb 1/400 1/100 
β-actin A5316 Sigma-Aldrich (St Louis, MO, 
USA) m 1/5,000   
ATP5H 17589-1-AP Proteintech (Chicago, USA) rb   1/100 
Anti-Manganese superoxide 
dismutaseSOD2 SOD-110 Stressgen (San Diego, USA) rb   1/100 
Anti-Histone H3K9me2 Ab1220 Abcam (Cambridge, UK) m   1/90 
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Table IV: Quantitative data of cells stained with Nissl stain and immunoreactive with 
antibodies against voltage dependent anion channel (VDAC), glial fibrillary acidic 
protein (GFAP), CD8 (reactive microglia), nucleolin (NCL), nucleoplasmin 3 (NPM3), 
histone H3K9me2, ATP5H protein and superoxide dismutase 2 (SOD2) in the 
mediodorsal thalamus in control and FFI cases. Values are expressed as mean values 
± SD. Assessed cell types are named in the left column excepting ATP5H and SOD2 
immunoreactive cells which are neurons in controls and glia in FFI cases.        
 
 
 Control  FFI 
Nissl (only neurons) 20.5 ± 2.01 0.9 ± 073 
VDAC (only neurons) 20.4 ± 2.06  1.3 ± 0.94 
GFAP  (astrocytes) 8.8 ± 2.09 35 ± 6.87 
CD68 (reactive microglia) 2.3 ± 0.94 18.4 ± 3.40
NCL (only neurons 6.8 ± 1.81 0 
NPM3 (only neurons) 6 ± 1.82 0 
H3K9me2 (only neurons) 21.8 ± 2.04 0 
ATP5H 23.7 ± 2.45 (neurons) 23 ± 3.52 (glia) 
SOD2 20.6 ± 1.83 (neurons) 25.5 ± 2.83 (glia)  
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Figure legends 
 
Figure 1: Mediodorsal thalamus A, B, E, F, I, J, M, N) and entorhinal cortex C, D, G, H, 
K, L, O, P) in age-matched control (A, C, E, G, I, K, M, O) and FFI (B, D, F, H, J, L, N, 
P) cases. Severe neuron loss is seen in the mediodorsal thalamus in FFI, whereas 
moderate neuron loss and spongiform change is observed in the entorhinal cortex in 
FFI. Increased numbers of GFAP-immunoreactive astrocytes are present in 
mediodorsal thalamus and entorhinal cortex in FFI compared with corresponding 
controls. Increased numbers of Iba1-immunoreactive cells and CD-68-positive cells are 
seen in the EC in six cases and in two of seven FFI cases (here illustrated) compared 
with controls. Paraffin sections, A-D: haematoxylin and eosin; E-H: GFAP 
immunohistochemistry; I-L: Iba1 immunohistochemistry; M-P: CD-68 
immunohistochemstry; immunohistochemical sections slightly counterstained with 
haematoxylin. A-P, bar in P = 55 µm. D1, H1, L1, P1, bar in P1 = 30 µm.        
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Figure 2: Mediodorsal nucleus of the thalamus (thal: A-C) and entorhinal cortex (EC: 
D-F) in control (A, B) and FFI (B, C, E, F) cases showing marked loss of neurons 
without spongiform change in the thalamus and moderate neuron loss and spongiform 
change in entorhinal cortex in FFI when compared with corresponding regions in 
controls. In FFI, no proteinase K-resistant PrP (PrPRes) is observed in the mediodorsal 
thalamus (C) whereas punctate, synaptic-like immunostaining is observed in the 
entorhinal cortex (F) processed in parallel. Paraffin sections, A, B, D, E Nissl staining, 
bar in E = 50 µm; C, F, PrP immunohistochemistry (3F4 antibody) following pre-
incubation with proteinase K, bar in F = 25 µm.    
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Figure 3: A) Western blot of subunits NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 8, 19 kDa (NDUFB8), succinate dehydrogenase complex, subunit B, iron 
sulphur (lp) (SDHB), ubiquinol-cytochrome c reductase core protein II (UQCRC2),  
cytochrome c oxidase subunit II (COX2) and ATP synthase, H+ transporting, 
mitochondrial F1 complex, and alpha subunit 1 (ATP5A) using OXPHOS antibody; ATP 
synthase, H+ transporting mitochondrial F1 complex, O subunit (ATP5O) and 
ubiquinol-cytochrome c reductase binding protein (UQCRB) antibodies in mediodorsal 
thalamus in FFI and control cases. β-actin and VDAC were used to normalize total 
protein and mitochondria protein loading, respectively.  
 
 
                       
                       
 
 
B) Densitometric analysis shows significant reduction of NDUFB8, SDHB, UQCRC2 
and COX2 normalized with β-actin and VDAC in FFI compared with controls. ATP5A 
and UQCRB protein levels were preserved. Results were analysed by Graphpad Prism 
with Student’s t test when the distribution was normal and with Mann-Whitney test if 
distribution was not normal as assessed with the Kolmogorov-Smirnov normality test. 
Differences are considered statistically significant at * p<0.05, ** p<0.01, *** p<0.001 
and **** p<0.0001. ATP5O shows a significant reduction when normalized with β-actin 
but only a trend with VDAC. 
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Figure 4: Mediodorsal nucleus of the thalamus in control (A, C, E, F) and FFI (B, D, F, 
H) cases. Nissl staining (A, B) shows marked decrease in the number of neurons in FFI 
when compared with controls. (VDAC) (C, D), (C, D) (SOD2) (E, F) immunoreactivity is 
found in mediodorsal thalamus in control (A, C, E) and FFI (B, D, F) cases). Decreased 
voltage-dependent anion channel (VDAC) (C, D) and ATP synthase, H+ transporting, 
mitochondrial Fo complex, subunit d (ATP5H) (E, F) immunoreactivity is found in the 
mediodorsal thalamus in FFI compared to controls due to the dramatic decrease in the 
number of neurons. However, ATP5H is observed in ractive glial cells. Weak 
superoxide dismutase 2 (SOD2) (G, H) immunoreactivity is seen in neurons in control 
cases which contrasts with enhanced SOD2 immunostaining in reacytive astrocytes in 
FFI. Paraffin sections, A, B: Nissl staining; C-H immunohistochemical sections slightly 
counterstained with haematoxylin. A-H, bar in H = 25 µm. F1, H1, bar in H1 = 10 µm.   
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Figure 5: mRNA expression of ribosomal proteins (RPL and RPS) in mediodorsal 
thalamus in FFI and controls. RPS17, RPS20, NMP1 and 28S rRNA are up-regulated 
in FFI cases using XPNPEP1 for normalisation.  Mean fold-change values for each 
group are compared with Student’s t test and differences were considered statistically 
significant at * p < 0.05. 
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Figure 6: Nucleolin (NCL) (A, B), NPM3 (C, D) and H3 dimethyl K9 (H3K9me2) (E, F) 
immunoreactivy is observed in neurons in the mediodorsal thalamus in controls (A, C, 
E). Weak NCL immunoreactivity is found in the nucleolus whereas strong NCL 
immunoreactivy is present in the neuronal cytoplasm. NPM3 immunoreactivity is 
observed in the nucleolus, whereas H3K9me2 immunolabelling is localized in the 
nucleus. Decreased NCL, NMP3 and H3K9me2 expression is found in FFI cases (B, D, 
E) due to the marked decrease in the number of neurons. Paraffin sections slightly 
counterstained with haematoxylin; bar = 25 µm.   
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Figure 7: A) Western blots of nucleolin, initiation (eIF2α, P- eIF2α, eIF5) and 
elongation factors (eEF1A, eEF2) in mediodorsal thalamus in FFI and control cases. β-
actin was used to normalize total protein. 
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B) Densitometric analysis shows significant reduction of NCL and eEF1A. Results were 
analysed by Graphpad Prism with Student’s t test when the distribution was normal and 
with Mann-Whitney test if distribution was not normal as assessed with the 
Kolmogorov-Smirnov normality test. Differences are considered statistically significant 
at * p<0.05. 
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Supplementary Tables 
 
Supplementary Table I: Gene expression of subunits of mitochondrial complexes in 
the mediodorsal thalamus in FFI and control cases normalized with XPNPEP1. 
 
 
Thalamus Probe Control FFI P value   
Complex I 
NDUFA2 1.02 ± 0.20 0.79 ± 0.17 0.06 - 
NDUFA7 1.02 ± 0.20 0.91 ± 0.34 0.50 - 
NDUFA10 1.00 ± 0.10 0.96 ± 0.13 0.49 - 
NDUFB3 1.02 ± 0.22 0.82 ± 0.15 0.10 - 
NDUFB7 1.02 ± 0.2 0.87 ± 0.26 0.31 - 
NDUFB10 1.02 ± 0.21 0.89 ± 0.23 0.34 - 
NDUFS7 1.02 ± 0.22 0.91 ± 0.20 0.37 - 
NDUFS8 1.01 ± 0.19 0.95 ± 0.41 0.73 - 
Complex II SDHB 1.03 ± 0.24 0.87 ± 0.17 0.21 - 
Complex III 
UQCR11 1.03 ± 0.26 0.94 ± 0.19 0.50 - 
UQCRB 1.06 ± 0.38 0.78 ± 0.31 0.20 - 
Complex IV 
COX7A2L 1.03 ± 0.27 0.87 ± 0.15 0.25 - 
COX7C 1.05 ± 0.37 1.01 ± 0.20 0.81 - 
Complex V 
  
ATP5D 1.02 ± 0.22 0.63 ± 0.08 0.004 ** 
ATP5G2 1.01 ± 0.13 1.36 ± 0.48 0.09 - 
ATP5H 1.02 ± 0.21 0.85 ± 0.20 0.18 - 
ATP5L 1.01 ± 0.19 0.98 ± 0.20  0.76 - 
ATP5O 1.02 ± 0.19 0.80 ± 0.19 0.09 - 
ATP6V0B 1.06 ± 0.39 0.87 ± 0.15 0.34 - 
ATP6V1H1 1.13 ± 0.64 0.73 ± 0.13 0.21 - 
 TOMM40 1.03 ± 0.25 0.80 ± 0.12 0.08 - 
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Supplementary Table II: Densitometric values of expression of mitochondrial proteins 
as revealed by western blotting in the mediodorsal thalamus in FFI cases and controls 
normalized with β-actin (A) and VDAC (B).    
 
A 
Protein Control FFI P value  
NDUFB8 0.62 ± 0.12 0.44 ± 0.11 0.0257 * 
SDHB 0.87 ± 0.11 0.65 ± 0.18 0.0426 * 
UQCRB 1.87 ± 0.21 1.70 ± 0.36 0.34 - 
UQCRC2 0.49 ± 0.09 0.38 ± 0.09 0.0462 * 
COX2 0.77 ± 0.14 0.54 ± 0.09 0.0071 ** 
ATP5A 0.89 ± 0.05 0.85 ± 0.19 0.69 - 
ATP5O 0.78 ± 0.20 0.52 ± 0.07 0.0227 * 
 
  
B 
Protein Control FFI P value  
NDUFB8 0.77 ± 0.06 0.52 ± 0.12 0.0087 ** 
SDHB 1.10 ± 0.13 0.79 ± 0.15 0.0035 ** 
UQCRB 0.94 ± 0.16 0.88 ± 0.18 0.61 - 
UQCRC2 0.62 ± 0.07 0.44 ± 0.07 0.0022 ** 
COX2 0.94 ± 0.06 0.58 ± 0.04 0.0001 **** 
ATP5A 1.21 ± 0.04 1.02 ± 0.23 0.08 - 
ATP5O 1.08 ± 0.23 0.78 ± 0.22 0.09 - 
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Supplementary Table III: Gene expression of nucleolar proteins. 18S and 28S rRNAS 
and ribosomal proteins in the mediodorsal thalamus in FFI and control cases 
normalized with XPNPEP1. 
Genes 
encoding 
for 
Probe Control FFI P Value 
  
Nucleolar 
proteins 
UBTF 1.00 ± 0.05 0.88 ± 0.12 0.09 - 
NCL 1.01 ± 0.17 1.05 ± 0.12 0.69 - 
NPM1 1.01 ± 0.14 1.36 ± 0.31 0.027 * 
rRNAs 
rRNA18S 1.01 ± 0.19  1.30 ± 0.46 0.24 - 
rRNA28S 1.12 ± 0.56 2.93 ± 1.64 0.0287 * 
Ribosomal 
proteins 
RPL5 1.01 ± 0.14 1.17 ± 0.15 0.09 - 
RPL7 1.03 ± 0.25 1.27 ± 0.11 0.13 - 
RPL21 1.05 ± 0.34 0.87 ± 0.37 0.40 - 
RPL22 1.00 ± 0.09 1.48 ± 0.56 0.09 - 
RPL23A 1.03 ± 0.27 1.14 ± 0.10 0.42 - 
RPL26 1.03 ± 0.27 0.80 ± 0.44 0.13 - 
RPL27 1.03 ± 0.25  1.44 ± 0.46 0.09 - 
RPL30 1.03 ± 0.27 1.33 ± 0.22 0.08 - 
RPL31 1.03 ± 0.30 1.23 ± 0.15 0.21 - 
RPS3A 1.02 ± 0.22 1.20 ± 0.21 0.19 - 
RPS5 1.01 ± 0.19 1.55 ± 0.63 0.07 - 
RPS6 1.00 ± 0.04 1.53 ± 0.59 0.08 - 
RPS10 1.01 ± 0.12 1.04 ± 0.15 0.66 - 
RPS13 1.02 ± 0.22 1.17 ± 0.16 0.24 - 
RPS17 1.01 ± 0.13 1.28 ± 0.18 0.016 * 
RPS20 1.02 ± 0.22 1.65 ± 0.51 0.0295 * 
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Supplementary Table IV: Densitometric values of expression of initiation and 
elongation factors of protein transcription in the mediodorsal thalamus in FFI cases and 
controls normalized with β-actin    
 Protein Control FFI P value   
NCL 1. 60 ± 0.33 1.04 ± 0.34 0.012 * 
eIF2α  1.16 ± 0.22 0.95 ± 0.14 0.06 - 
P- eIF2α 1.90 ± 0.65 1.35 ± 0.53 0.13 - 
eIF5 2.12 ± 0.95 2.33 ± 1.08 0.72 - 
eEF1A 2.07 ± 0.17 1.59 ± 0.44 0.021 * 
eEF2 1.17 ± 0.22 1.18 ± 0.30 0.91 - 
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